OCGN - Ocugen

-

$undefined

N/A

(N/A)

Ocugen NasdaqCM:OCGN Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Location: 11 Great Valley Parkway, Malvern, PA, 19355, United States | Website: https://www.ocugen.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

215.5M

Cash

37.8M

Avg Qtr Burn

-12.73M

Short % of Float

23.74%

Insider Ownership

1.60%

Institutional Own.

26.46%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
OCU400 Details
Retinitis Pigmentosa

BLA

Submission

Phase 3

Initiation

OCU410ST Details
Stargardt disease, Rare genetic disease

Phase 2/3

Initiation

OCU410 Details
Geographic atrophy, Age-related macular degeneration

Phase 1/2

Data readout

OCU400 Details
Eye disease , Leber congenital amaurosis, Retinitis Pigmentosa

Phase 1/2

Data readout

OCU200 Details
Diabetic macular edema

Phase 1

Data readout

Phase 1

Initiation

COVAXIN (BBV152) Details
COVID-19, Infectious disease

Failed

Discontinued